S-A. Im

1.8k total citations
85 papers, 1.1k citations indexed

About

S-A. Im is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, S-A. Im has authored 85 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 59 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in S-A. Im's work include Advanced Breast Cancer Therapies (50 papers), Cancer Treatment and Pharmacology (39 papers) and HER2/EGFR in Cancer Research (37 papers). S-A. Im is often cited by papers focused on Advanced Breast Cancer Therapies (50 papers), Cancer Treatment and Pharmacology (39 papers) and HER2/EGFR in Cancer Research (37 papers). S-A. Im collaborates with scholars based in South Korea, United States and Spain. S-A. Im's co-authors include Y-J. Bang, S-B. Kim, Tae‐Yop Kim, Daehee Hwang, Hyoung‐Pyo Kim, Elaine Kilgour, Shethah Morgan, Javier Cortés, Paul R. Gavine and Won Ho Kim and has published in prestigious journals such as Cancer Research, Oncogene and British Journal of Cancer.

In The Last Decade

S-A. Im

78 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S-A. Im South Korea	18	799	454	324	242	163	85	1.1k
Zanete Zvirbule Latvia	17	850 1.1×	506 1.1×	218 0.7×	221 0.9×	139 0.9×	45	1.2k
Andrea Fontana Italy	19	549 0.7×	335 0.7×	285 0.9×	238 1.0×	74 0.5×	50	1.0k
Erin Macrae United States	13	708 0.9×	445 1.0×	250 0.8×	360 1.5×	68 0.4×	20	1.0k
Gaia Griguolo Italy	24	1.1k 1.3×	431 0.9×	269 0.8×	553 2.3×	290 1.8×	87	1.4k
Anastasia G Eleftheraki Greece	20	612 0.8×	316 0.7×	357 1.1×	240 1.0×	138 0.8×	37	1.2k
Rebecca Moroose United States	9	747 0.9×	357 0.8×	191 0.6×	190 0.8×	217 1.3×	23	1.0k
Frédérique Berger France	19	517 0.6×	323 0.7×	420 1.3×	411 1.7×	105 0.6×	64	1.0k
Marta Bonotto Italy	18	695 0.9×	443 1.0×	233 0.7×	368 1.5×	87 0.5×	52	1.0k
Jorge Chaves United States	16	909 1.1×	365 0.8×	211 0.7×	147 0.6×	161 1.0×	41	1.2k
Marta Jimenez France	13	888 1.1×	944 2.1×	360 1.1×	415 1.7×	97 0.6×	51	1.4k

Countries citing papers authored by S-A. Im

Since Specialization

Citations

This map shows the geographic impact of S-A. Im's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S-A. Im with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S-A. Im more than expected).

Fields of papers citing papers by S-A. Im

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S-A. Im. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S-A. Im. The network helps show where S-A. Im may publish in the future.

Co-authorship network of co-authors of S-A. Im

This figure shows the co-authorship network connecting the top 25 collaborators of S-A. Im. A scholar is included among the top collaborators of S-A. Im based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S-A. Im. S-A. Im is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmid, Peter, Hao‐Chien Wang, Y.H. Park, et al.. (2025). 555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study. Annals of Oncology. 36. S413–S414. 1 indexed citations

Barroso‐Sousa, Romualdo, Y.H. Park, C. Saura Manich, et al.. (2025). LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest. Annals of Oncology. 36. S1563–S1564.

Geyer, Charles E., Chiun‐Sheng Huang, Carlos H. Barrios, et al.. (2025). LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. Annals of Oncology. 36. S1556–S1557. 1 indexed citations

Barrios, Carlos H., Aditya Bardia, Xin Hu, et al.. (2025). 299MO DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC). ESMO Open. 10. 104871–104871. 1 indexed citations

Saura, Cristina, Javier Cortés, Shanu Modi, et al.. (2025). Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03. Annals of Oncology. 37(3). 353–363.

Ueno, Naoto T., Filipa Cardoso, Toshinari Yamashita, et al.. (2024). 188P A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor-positive (HR+), HER2-low metastatic breast cancer (mBC). ESMO Open. 9. 103210–103210. 2 indexed citations

Dent, R., Fabrice André, Anthony Gonçalvès, et al.. (2024). 180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC). ESMO Open. 9. 103202–103202. 3 indexed citations

Shapiro, Geoffrey I., Bristi Basu, Anthony B. El-Khoueiry, et al.. (2023). 821TiP Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis). Annals of Oncology. 34. S542–S542. 2 indexed citations

Jhaveri, Komal, X. Cynthia, Elgene Lim, et al.. (2023). 383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study. Annals of Oncology. 34. S338–S339. 9 indexed citations

10.

Eralp, Yeşim, Hikmat Abdel‐Razeq, S-A. Im, et al.. (2023). 456P Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC). Annals of Oncology. 34. S372–S373. 1 indexed citations

11.

Modi, Shanu, William Jacot, Hiroji Iwata, et al.. (2023). 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. Annals of Oncology. 34. S334–S335. 28 indexed citations

12.

Schmid, Peter, Javier Cortés, Rebecca Dent, et al.. (2023). LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. Annals of Oncology. 34. S1257–S1257. 20 indexed citations

13.

Azim, Hamdy A., Nagi S. El Saghir, Yoon Sim Yap, et al.. (2023). 402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study. Annals of Oncology. 34. S350–S351.

14.

Metzger, Otto, Chiara Lambertini, IE Krop, et al.. (2021). 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC). Annals of Oncology. 32. S37–S38. 3 indexed citations

15.

Im, S-A., Javier Cortés, Oleg Lipatov, et al.. (2020). 44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation. Annals of Oncology. 31. S1258–S1258. 4 indexed citations

16.

Turner, Nicholas C., Komal Jhaveri, Kevin Kalinsky, et al.. (2020). 355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC). Annals of Oncology. 31. S391–S392. 6 indexed citations

17.

Park, Y.H., KH Lee, Kyung Hae Jung, et al.. (2017). A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial. Annals of Oncology. 28. v74–v74. 3 indexed citations

18.

Pivot, Xavier, Igor Bondarenko, Zbigniew Nowecki, et al.. (2017). One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment. Annals of Oncology. 28. v45–v45. 6 indexed citations

19.

Im, S-A., Norikazu Masuda, Y-H Im, et al.. (2017). Efficacy and safety of palbociclib plus endocrine therapy in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the Asia-Pacific region: Data from PALOMA-2 and -3. Annals of Oncology. 28. x27–x27. 2 indexed citations

20.

Ahn, Hyo Seop, Sang‐Ho Jeong, HJ Lee, et al.. (2014). Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer. British journal of surgery. 101(12). 1560–1565. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact